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FEBS Letters 581 (2007) 343Pascale Cossart has always focussed on following her interests.
During her M.Sc., she transferred to Georgetown University
(USA) for a year. It was a turning point. ‘‘I heard how Fred-
erick Sanger sequenced the protein insulin. I was fascinated,
quite frankly,’’ she says, ‘‘for me it was the beauty of chemistry
applied to biology.’’ Her PhD (Pasteur Institute, Paris) fol-
lowed, during which she sequenced an E. coli protein. Through
the following years, her research interests continued evolving,
from sequencing proteins to sequencing genes, to studying
DNA–protein interactions, and ﬁnally, tackling the problem
of pathogenicity. Pascale is currently the Director of the Cell
Biology and Infection Department, and Head of the Bacte-
ria-Cell Interactions Unit at the Pasteur Institute (Paris,
France). She is also the foremost authority on food-borne
pathogen Listeria monocytogenes. Pascale edits for FEBS Let-
ters papers dealing with microbiology, toxins, bacterial inva-
siveness, and actin-based motility.What does your lab do?
We decipher the molecular mechanisms that underlie viru-
lence, using the bacterial pathogen Listeria monocytogenes as
a model organism, and one of our goals is to generalize our dis-
coveries to other pathogenic bacteria. We identify and charac-
terize components that are critical for infection, in both the
bacteria and the host, and investigate their interactions, and
the resulting signals. We want to understand the time-scale of
the signalling events. We validate our results in animal models,
with knock-out and transgenic mice. Our lab is multidisciplin-
ary. We use techniques from molecular biology, biochemistry,
cell biology, post-genomics and also transgenesis.How does a pathogenic bacterium invade cells?
If a Listeria bacterium reaches the intestinal tract, it can induce
intestinal cells to phagocytose it in a vacuole. The bacterium
then lyses the vacuole and moves actively throughout the cell,
dividing and multiplying. Sometimes, one or more of these
bacteria will push a protrusion into a neighbouring cell and
invade it too. So tissues are infected, by direct cell to cell.
The bacteria are clever enough to induce anti-apoptotic mech-
anisms during this process. Pathogenic bacteria do not want to
be too virulent, they need somewhat healthy cells!Virulence and pathogenicity, what is the diﬀerence?
An organism is pathogenic when it is capable of harming its
host, while virulence refers to the degree of harm caused.
The level of this interaction depends both on the organism
and the host. For instance, a bacterium can be virulent for0014-5793/$32.00  2007 Published by Elsevier B.V. on behalf of the Feder
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immune response.Will a pill ever be developed protect vacationers and travellers
from bacterial infections?
I would not advise taking such an anti-bacterial pill, because
commensal bacteria are in your body, that are critical for your
innate immune response. It is important to keep the antibacte-
rial drugs for when a real robust infection occurs. The emerg-
ing problem is that more and more bacteria are resistant to
antibiotics. And this is why it is important for researchers like
us to pave the way for new drugs.What discoveries could lead to new drugs?
Understanding, for instance, how a bacterium enters a cell and
circumvents the innate immune response. Our research has
already resulted in an unexpected discovery; one that may help
in treating cancer. We just deposited a patent dealing with the
interaction between the bacterial protein InlB and the growth
factor receptor, Met [1]. We noticed that InlB causes Met to
endocytose much more quickly than a normal ligand does.
We also knew that in many types of cancer, this receptor has
a mutation that constitutively activates it, so the ability to
downregulate this receptor may have an application as an
anti-cancer drug.What do you consider your best papers?
Our 1992 Cell paper was ground-breaking because it describes
ActA, a protein that mediates actin-based motility in Listeria
[2]. This discovery was a happy accident, we found this gene
when we were looking for lecithinase mutants, and stumbled
across one that was totally avirulent, and completely non-mo-
tile inside mammalian cells. The actA gene and the lecithinase
gene are part of the same operon, hence the phenotype of our
mutant! Our 1996 Cell paper reports E-cadherin as the recep-
tor that Listeria binds to before entering cells [3]. It was perfect
hindsight to ﬁnd that Listeria indeed uses this molecule. I had
previously heard Rolf Kemler give a talk about E-cadherin at a
conference, and I thought that it would make the ideal receptor
for a pathogen. And it is amazing that E-cadherin was discovered
here at the Pasteur Institute [4]. Prime examples of serendipity.References
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